AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17159759 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 306
Study 15480327 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM-impermeable covers
Number of subjects: 52
Study 15480327 — intervention group
Group type: COMPARATOR
Intervention: Placebo covers
Number of subjects: 52
Study 12404675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine (37.5 mg/day)
Number of subjects: 178
Study 12404675 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 178
Study 12404675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 178
Study 12404675 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 178
Study 9593759 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide (8 pmol kg-1 min-1)
Number of subjects: 19
Study 9593759 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (154 mmol liter-1 NaCl)
Number of subjects: 19
Study 9593759 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 19
Study 8005273 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial priming with oral micronized E2, 4 mg/d for 14 days; Progesterone replacement IM P in oil, 50 mg/d for 14 days.
Number of subjects: 14
Study 8005273 — intervention group
Group type: COMPARATOR
Intervention: Control group continued the same E2 regimen during the luteal phase.
Number of subjects: 14
Study 2680288 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg twice or 3 times a day)
Number of subjects: 60
Study 2680288 — intervention group
Group type: COMPARATOR
Intervention: Probucol (500 mg twice a day)
Number of subjects: 60
Study 1096704 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfamethizole, nitrofurantoin, methenamine mandelate
Number of subjects: 249
Study 1096704 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 249
Study 30898253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SeQuent SCB, 4 μg/mm2)
Number of subjects: 50
Study 30898253 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-coated balloon (SeQuent Please Neo, 3 μg/mm2)
Number of subjects: 50
Study 30898253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study 27189694 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) medication adherence
Number of subjects: 139
Study 27189694 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral adherence measures (e.g., electronic monitoring)
Number of subjects: 139
Study 25996285 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (women's and men's formula) for 16 weeks
Number of subjects: 116
Study 25996285 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 116
Study 23587106 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Robot-Assisted Training (BRT)
Number of subjects: 53
Study 23587106 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Robot-Assisted Training (URT)
Number of subjects: 53
Study 23587106 — intervention group
Group type: COMPARATOR
Intervention: Control Treatment (CT)
Number of subjects: 53
Study 21793690 — intervention group
Group type: EXPERIMENTAL
Intervention: General Psychotherapy (GPT)
Number of subjects: 67
Study 21793690 — intervention group
Group type: COMPARATOR
Intervention: General Psychotherapy Minus Clarification (GPT-C)
Number of subjects: 67
Study 19372653 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban 30 mg/day
Number of subjects: 18000
Study 19372653 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg/day
Number of subjects: 18000
Study 17448768 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy (LP)
Number of subjects: 102
Study 17448768 — intervention group
Group type: COMPARATOR
Intervention: Open circumumbilical pyloromyotomy (OP)
Number of subjects: 102
Study 15353532 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide 2.5 mg
Number of subjects: 434
Study 15353532 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide 5.0 mg
Number of subjects: 434
Study 15353532 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide 7.5 mg
Number of subjects: 434
Study 15353532 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine hydrobromide 10 mg
Number of subjects: 434
Study 15353532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 434
Study 11500334 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP), 336 microg/d
Number of subjects: 24
Study 11500334 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 24
Study 11500334 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 24
Study 9505743 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask anaesthesia
Number of subjects: 15
Study 9505743 — intervention group
Group type: COMPARATOR
Intervention: Face mask anaesthesia
Number of subjects: 15
Study 9505743 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding nitrous oxide until laryngeal mask insertion
Number of subjects: 15
Study 8001713 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients
Number of subjects: 204
Study 8001713 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with macroangiopathy and/or microangiopathy
Number of subjects: 204
Study 8001713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients without vascular affection
Number of subjects: 204
Study 8001713 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiobarbituric acid-reactive substances
Number of subjects: 204
Study 2605069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1600 mg orally before anaesthesia
Number of subjects: 53
Study 2605069 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets before anaesthesia
Number of subjects: 53
Study 1099184 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Continuous Negative Pressure (ECNP)
Number of subjects: 23
Study 1099184 — intervention group
Group type: COMPARATOR
Intervention: Late Continuous Negative Pressure (LCNP)
Number of subjects: 23
Study 31424550 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 66
Study 31424550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 31424550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 66
Study 31424550 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-resistant isolates
Number of subjects: 66
Study 28823365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FT group, n=54)
Number of subjects: 128
Study 28823365 — intervention group
Group type: COMPARATOR
Intervention: Conventional process (NFT group, n=74)
Number of subjects: 128
Study 25615708 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling intervention (video created from personal stories)
Number of subjects: 539
Study 25615708 — intervention group
Group type: COMPARATOR
Intervention: Personal risk tool intervention (instrument estimating level of personal cancer risk)
Number of subjects: 539
Study 22921476 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone (BUP)
Number of subjects: 1269
Study 22921476 — intervention group
Group type: COMPARATOR
Intervention: Methadone (MET)
Number of subjects: 1269
Study 20943714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based gait training
Number of subjects: 30
Study 20943714 — intervention group
Group type: COMPARATOR
Intervention: Traditional gait training programme (Control)
Number of subjects: 30
Study 18202589 — intervention group
Group type: EXPERIMENTAL
Intervention: Pueraria mirifica (20, 30, or 50 mg once daily for 24 weeks)
Number of subjects: 71
Study 18202589 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsules once daily for 24 weeks)
Number of subjects: 71
Study 18202589 — intervention group
Group type: COMPARATOR
Intervention: Pueraria mirifica and Placebo
Number of subjects: 71
Study 16862360 — intervention group
Group type: EXPERIMENTAL
Intervention: Enameloplasty sealant technique (EST)
Number of subjects: 162
Study 16862360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup-shaped brush sealant technique (CST)
Number of subjects: 162
Study 16151033 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel with aspirin (C+ASA)
Number of subjects: 70
Study 16151033 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (ASA)
Number of subjects: 70
Study 12830063 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 157
Study 12830063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 157
Study 10524785 — intervention group
Group type: EXPERIMENTAL
Intervention: Omafilcon A lenses (Proclear; Biocompatibles)
Number of subjects: 40
Study 10524785 — intervention group
Group type: COMPARATOR
Intervention: Etafilcon A lenses (Acuvue; Vistakon)
Number of subjects: 40
Study 10524785 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic group
Number of subjects: 40
Study 10524785 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic group
Number of subjects: 40
Study 10524785 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic hydrogel contact lens wearers
Number of subjects: 40
Study 7741782 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (250 mg) plus bromhexine (8 mg) (Drug AB)
Number of subjects: 392
Study 2290329 — intervention group
Group type: EXPERIMENTAL
Intervention: fenigidin
Number of subjects: 14
Study 2290329 — intervention group
Group type: EXPERIMENTAL
Intervention: cordafen
Number of subjects: 14
Study 2290329 — intervention group
Group type: EXPERIMENTAL
Intervention: corinfar
Number of subjects: 14
Study 7028298 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 131
Study 31919692 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 77911
Study 31919692 — intervention group
Group type: EXPERIMENTAL
Intervention: Current HRT usage
Number of subjects: 77911
Study 29802080 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive dual-task training (n = 65)
Number of subjects: 121
Study 29802080 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated dual-task training (n = 56)
Number of subjects: 121
Study 29802080 — intervention group
Group type: COMPARATOR
Intervention: Control period (two baseline measurements)
Number of subjects: 121
Study 26443067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord group (Ultrapack, SilTrax AS)
Number of subjects: 40
Study 26443067 — intervention group
Group type: COMPARATOR
Intervention: Cordless group (Expasyl, Traxodent Hemodent paste)
Number of subjects: 40
Study 26443067 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Cord and Cordless)
Number of subjects: 40
Study 26443067 — intervention group
Group type: EXPERIMENTAL
Intervention: Expasyl (Cordless)
Number of subjects: 40
Study 26443067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord group
Number of subjects: 40
Study 26443067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord and Cordless techniques
Number of subjects: 40
Study 24154820 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosure (specific supplement enriched with n-3 polyunsaturated fatty acids, fiber, proteins, and electrolytes)
Number of subjects: 26
Study 24154820 — intervention group
Group type: COMPARATOR
Intervention: Standard-Isosource (standard supplement)
Number of subjects: 26
Study 23829674 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite heart failure service
Number of subjects: 33
Study 23829674 — intervention group
Group type: COMPARATOR
Intervention: Standard care without onsite heart failure service
Number of subjects: 33
Study 23829674 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for heart failure
Number of subjects: 33
Study 23829674 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement in healthcare decisions
Number of subjects: 33
Study 20410414 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual CT sonography
Number of subjects: 59
Study 20410414 — intervention group
Group type: COMPARATOR
Intervention: Conventional sonography
Number of subjects: 59
Study 20410414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodule size, echo pattern, and location
Number of subjects: 59
Study 20410414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodules 10 mm in diameter or smaller
Number of subjects: 59
Study 18523220 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer (1 or more affected first-degree relatives)
Number of subjects: 1087
Study 18523220 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer (1 affected first-degree relative)
Number of subjects: 1087
Study 18523220 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer (2 or more affected first-degree relatives)
Number of subjects: 1087
Study 18523220 — intervention group
Group type: COMPARATOR
Intervention: No family history of colorectal cancer
Number of subjects: 1087
Study 18523220 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of colorectal cancer
Number of subjects: 1087
Study 16564279 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-extracorporeal circulation (MECC) system (group A)
Number of subjects: 60
Study 16564279 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass (group B)
Number of subjects: 60
Study 12673176 — intervention group
Group type: EXPERIMENTAL
Intervention: I-123 MIBG imaging and HRV analysis
Number of subjects: 17
Study 12673176 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of I‐123 MIBG heart‐mediastinal ratio and HRV 5‐minute low‐frequency variables
Number of subjects: 17
Study 10911790 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved needle technique
Number of subjects: 0
Study 10911790 — intervention group
Group type: COMPARATOR
Intervention: Conventional straight needle
Number of subjects: 0
Study 9387758 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (RAG I and II plus whole embryo extract)
Number of subjects: 30
Study 9387758 — intervention group
Group type: COMPARATOR
Intervention: Discombined group (RAG I and II only)
Number of subjects: 30
Study 9387758 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental study in animal models (treated group)
Number of subjects: 30
Study 9387758 — intervention group
Group type: COMPARATOR
Intervention: Control group (animal models)
Number of subjects: 30
Study 1401688 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric evaluation and management program
Number of subjects: 200
Study 1401688 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 200
Study 3881211 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam
Number of subjects: 181
Study 3881211 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 181
Study 30694099 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus plantarum IS-10506)
Number of subjects: 38
Study 30694099 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 38
Study 30694099 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic and Zinc
Number of subjects: 38
Study 30694099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29893604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip and core-focused rehabilitation (n = 111)
Number of subjects: 199
Study 29893604 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-focused rehabilitation (n = 88)
Number of subjects: 199
Study 27179988 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg loading dose followed by 81 mg/d)
Number of subjects: 390
Study 27179988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 27179988 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 390
Study 25122186 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy
Number of subjects: 935
Study 25122186 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated left ventricular filling pressure (E/E')
Number of subjects: 935
Study 25122186 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pulmonary artery pressure (tricuspid regurgitation velocity)
Number of subjects: 935
Study 25122186 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome of cardiovascular death, heart failure hospitalization, or aborted cardiac arrest
Number of subjects: 935
Study 23168146 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (Group A, Beck positive)
Number of subjects: 120
Study 23168146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group B, Beck positive)
Number of subjects: 120
Study 23168146 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (Group C, Beck negative)
Number of subjects: 120
Study 23168146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group D, Beck negative)
Number of subjects: 120
Study 23168146 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C, D)
Number of subjects: 120
Study 23168146 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (Group A)
Number of subjects: 120
Study 20592433 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health literacy intervention
Number of subjects: 909
Study 20592433 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (400 mcg/d) + vitamin B12 (100 mcg/d)
Number of subjects: 909
Study 20592433 — intervention group
Group type: COMPARATOR
Intervention: Physical activity promotion
Number of subjects: 909
Study 20592433 — intervention group
Group type: COMPARATOR
Intervention: Nutrition promotion control
Number of subjects: 909
Study 18588848 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 microg administered vaginally twice, 6 and 12 hours before hysteroscopy
Number of subjects: 60
Study 18588848 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hexetidine pill) administered vaginally twice, 6 and 12 hours before hysteroscopy
Number of subjects: 60
Study 16087019 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled temperature radiofrequency (RF)
Number of subjects: 70
Study 16087019 — intervention group
Group type: COMPARATOR
Intervention: Injection snoreplasty (IS)
Number of subjects: 70
Study 12544159 — intervention group
Group type: EXPERIMENTAL
Intervention: Home interferential current therapy (IFC)
Number of subjects: 87
Study 12544159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no current)
Number of subjects: 87
Study 10479130 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor-containing triple therapy for 2 years
Number of subjects: 19
Study 7488802 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 28
Study 7488802 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 28
Study 7488802 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term outcome
Number of subjects: 28
Study 1891022 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release aspirin (75 mg, releasing 10 mg per hour)
Number of subjects: 0
Study 1891022 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release aspirin (162.5 mg loading dose)
Number of subjects: 0
Study 1891022 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release aspirin (75 mg)
Number of subjects: 0
Study 1891022 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release aspirin (75 mg)
Number of subjects: 0
Study 6215855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bound niacin (BN) - 35 mg niacin
Number of subjects: 3
Study 6215855 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkali-treated bound niacin (ABN) - 24 mg pure nicotinic acid
Number of subjects: 3
Study 6215855 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid - 24 mg
Number of subjects: 3
Study 28847468 — intervention group
Group type: EXPERIMENTAL
Intervention: slow‐release melatonin at a dose of 3mg
Number of subjects: 100
Study 28847468 — intervention group
Group type: COMPARATOR
Intervention: oral placebo
Number of subjects: 100
Study 25318574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed glaucoma valve (AGV)
Number of subjects: 29
Study 25318574 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 μm Gold Micro‐Shunt (GMS)
Number of subjects: 29
Study 25318574 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 μm Gold Micro‐Shunt (GMS)
Number of subjects: 29
Study 24477842 — intervention group
Group type: COMPARATOR
Intervention: Fluoride-free toothpaste (Control)
Number of subjects: 16
Study 24477842 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste A (0.4% SnF2, Solidox)
Number of subjects: 16
Study 24477842 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste B (0.454% SnF2, Oral-B(®))
Number of subjects: 16
Study 24477842 — intervention group
Group type: EXPERIMENTAL
Intervention: SnF2 solution (0.4%, 1,000 ppm F)
Number of subjects: 16
Study 23216685 — intervention group
Group type: EXPERIMENTAL
Intervention: CareWell-primary care program
Number of subjects: 600
Study 23216685 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 600
Study 20363764 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading 4-8 hours before PCI
Number of subjects: 503
Study 20363764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study 17435356 — intervention group
Group type: COMPARATOR
Intervention: Shinrin-yoku (forest atmosphere)
Number of subjects: 12
Study 16116130 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid drink containing l-tryptophan
Number of subjects: 76
Study 16116130 — intervention group
Group type: COMPARATOR
Intervention: Amino acid drink omitting l-tryptophan
Number of subjects: 76
Study 12099919 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in a stroke unit (SU)
Number of subjects: 477
Study 12099919 — intervention group
Group type: COMPARATOR
Intervention: General medical wards (GMWs)
Number of subjects: 477
Study 12099919 — intervention group
Group type: COMPARATOR
Intervention: Minor stroke (SSS-score >30)
Number of subjects: 477
Study 12099919 — intervention group
Group type: COMPARATOR
Intervention: Severe stroke
Number of subjects: 477
Study 12099919 — intervention group
Group type: EXPERIMENTAL
Intervention: SSS-score below 30
Number of subjects: 477